Abstract

ORPHAN DISEASES AND THEIR PHARMACOLOGICAL MANAGEMENT: DRUG DEVELOPMENT, MECHANISMS OF ACTION, AND MONITORING CONSIDERATIONS

Mr. Mahesh Nilesh Junagade*, Dr. Vishal Sunil Gujare, Mr. Aditya Rajesh Jakhad

Abstract

Orphan drugs are pharmaceutical agents developed for the treatment and prevention of rare health conditions, commonly referred to as orphan diseases. These medications are often difficult to obtain because of their high cost and the limited amount of research conducted in this area. The occurrence of rare diseases differs from one country to another, depending largely on population characteristics and demographic factors. The Food and Drug Administration (FDA) has approved more than 770 drugs, including 77 that have received orphan drug designation. Several of these medications, primarily identified and developed by the pharmaceutical industry, are considered highly valuable but are associated with significant expense. The use of orphan drugs requires monitoring of specific clinical parameters. Therapeutic supervision should be tailored according to the patient’s physical status and the seriousness of the condition. This review article intends to provide a comprehensive evaluation of the development of orphan drugs and their monitoring practices.

Keywords: Orphan diseases, Orphan drugs-development, Therapeutic monitoring, Disease severity, Monitoring criteria.